Precision Biosciences (DTIL) Operating Margin (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Operating Margin data on file, last reported at 83.73% in Q1 2026.

• Operating Margin for Q1 2026 came in at 83.73%, up 7616454.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 86.77% (down 57.0% YoY), and the FY2025 annual result was 152.19%, down 11411.0% from the prior year.
• Operating Margin retreated to 83.73% in Q1 2026 per DTIL's latest filing, from 36.57% in the prior quarter.
• Over five years, Operating Margin peaked at 48.39% in Q2 2024 and troughed at 158976.92% in Q3 2025.
• A 5-year average of 21574.1% and a median of 199.32% in 2022 frame the typical range for Operating Margin.
• The sharpest annual moves came in 2025 and 2026: Operating Margin sank 15528335 bps in 2025, then soared 7616454 bps in 2026.
• A 5-year view of Operating Margin shows it stood at 114.26% in 2022, then slumped by 85 bps to 211.57% in 2023, then tumbled by 1741 bps to 3894.36% in 2024, then soared by 101 bps to 36.57% in 2025, then tumbled by 329 bps to 83.73% in 2026.
• Business Quant data shows DTIL's Operating Margin at 83.73% in Q1 2026, 36.57% in Q4 2025, and 158976.92% in Q3 2025.